Sex differences in cortisol response to reboxetine.
This study examined the cortisol response to reboxetine in a sample of healthy men and women. Forty healthy volunteers were randomly allocated to one of two treatment groups: placebo or 4 mg reboxetine under double-blind conditions. Saliva cortisol was measured pre, 1 and 1.5 h post-treatment. Mood and side-effects were also measured. A single oral dose of 4 mg reboxetine did not affect positive or negative mood but did produce some side-effects. It was also sufficient to increase cortisol release 1.5 h post-treatment compared to placebo. In addition, reboxetine lead to a significantly increased cortisol release in male compared to female volunteers. The results suggest that healthy male volunteers are more responsive to challenge with a noradrenergic compound than females.
Tse
Wai S
WS
Section of Clinical Psychopharmacology, Institute of Psychiatry, King's College London, London, UK. sswstse@cityu.edu.hk
Bond
Alyson J
AJ
D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D009638:Norepinephrine / Q000097:blood; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D012463:Saliva / Q000378:metabolism; D012727:Sex Characteristics
D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine; D006854:Hydrocortisone; D009638:Norepinephrine